Market Overview

GlaxoSmithKline Expands Its Portfolio Of Medicines In The US For Patients With Asthma And COPD


GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the simultaneous availability of two of its recently approved products for the treatment of asthma and COPD to retail pharmacies in the US. Over the past 15 months, GSK has launched four inhaled respiratory therapies in the US, all delivered in its Ellipta® inhaler.

Arnuity(TM) Ellipta(R) is now available in the US for once-daily maintenance treatment of asthma. Arnuity Ellipta is available in two approved doses, 100mcg and 200mcg.
Arnuity™ Ellipta (fluticasone furoate inhalation powder) is a once-daily inhaled corticosteroid (ICS) medicine for the maintenance treatment of asthma. It is the first product in the Ellipta inhaler for the treatment of asthma to be introduced in the US.

Arnuity Ellipta is indicated for once-daily maintenance treatment of asthma as prophylactic therapy in patients aged 12 years and older. Arnuity Ellipta is not indicated for the relief of acute bronchospasm. It acts to reduce inflammation associated with asthma and helps to prevent and control the symptoms of asthma.

Arnuity Ellipta is available in two approved doses, 100mcg and 200mcg.

GSK also announced today that Incruse® Ellipta® (umeclidinium bromide), an anticholinergic indicated for the long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema, is now available to retail pharmacies in the US. Incruse is GSK's first anticholinergic monotherapy, a type of bronchodilator that can relax airway smooth muscles and improve airflow in and out of the lungs. Incruse Ellipta is available as 62.5mcg of umeclidinium dry inhalation powder, administered once-daily using the Ellipta inhaler.

"We're excited to share this news with patients. Forty years after the launch of our first respiratory therapy, we remain committed to innovation and helping a wide range of appropriate patients. These are the third and fourth respiratory products we've introduced since October 2013 in our patented Ellipta inhaler," said Jorge Bartolome, Senior Vice President of the GSK Respiratory Business Unit in the US. "The Ellipta allows for a common inhaler platform across our inhaled therapies approved since 2013."

GSK has made available a new "FREE to you for 12 months" coupon for Incruse Ellipta and Arnuity Ellipta. The savings offer coupon will pay the entire out-of-pocket (OOP) cost for eligible commercial and cash patients for up to twelve months. (Eligibility and other limitations apply.) This new "FREE to you for 12 months" savings offer is also available with some of our other GSK products. For more information, visit

Full U.S. Prescribing Information, including Patient Information Leaflets, is available at For images of Arnuity Ellipta and Incruse Ellipta, please see our press kit.


Related Articles (GSK)

View Comments and Join the Discussion!

Posted-In: News FDA Press Releases